Savara (SVRA) Receivables - Other (2010 - 2016)
Savara (SVRA) reported Receivables - Other of $400000.0 for Q4 2016, up 1270.57% on a QoQ basis from $29185.0 in Q3 2013.
Savara (SVRA) has 5 years of Receivables - Other data on file, last reported at $400000.0 in Q4 2016.
- Quarterly Receivables - Other changed N/A year-over-year to $400000.0 in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $400000.0 (changed N/A YoY) and the FY2016 annual result came in at $400000.0, changed N/A from the prior year.
- Receivables - Other grew to $400000.0 in Q4 2016 per SVRA's latest filing, from $29185.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $400000.0 in Q4 2016 and bottomed at $9659.0 in Q2 2013.
- The 3-year median for Receivables - Other is $15316.0 (2012), against an average of $64002.8.
- The widest annual swing landed in 2012, when Receivables - Other soared 7849.45%; it then slumped 55.16% in 2013.
- Tracing SVRA's Receivables - Other over 3 years: stood at $15689.0 in 2012, then soared by 86.02% to $29185.0 in 2013, then surged by 1270.57% to $400000.0 in 2016.
- Per Business Quant, the three latest SVRA Receivables - Other figures stand at $400000.0 (Q4 2016), $29185.0 (Q3 2013), and $9659.0 (Q2 2013).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 400,000.00 |
| Dec 31, 2016 | 400,000.00 |
| Sep 30, 2013 | 29,185.00 |
| Sep 30, 2013 | 29,185.00 |
| Jun 30, 2013 | 9,659.00 |
| Jun 30, 2013 | 9,659.00 |
| Mar 31, 2013 | 10,831.00 |
| Mar 31, 2013 | 10,831.00 |
| Dec 31, 2012 | 15,689.00 |
| Dec 31, 2012 | 15,689.00 |
| Sep 30, 2012 | 10,172.00 |
| Sep 30, 2012 | 10,172.00 |
| Jun 30, 2012 | 21,543.00 |
| Jun 30, 2012 | 21,543.00 |
| Mar 31, 2012 | 14,943.00 |
| Mar 31, 2012 | 14,943.00 |
| Dec 31, 2011 | 17,245.00 |
| Dec 31, 2011 | 17,245.00 |
| Sep 30, 2011 | 6,869.00 |
| Sep 30, 2011 | 6,869.00 |
| Jun 30, 2011 | 271.00 |
| Jun 30, 2011 | 271.00 |
| Dec 31, 2010 | 1,980.00 |
| Dec 31, 2010 | 1,980.00 |